• Biomolecules & Therapeutics
• /
• 제30권5호
• /
• pp.435-446
• /
• 2022

The present study evaluated the anti-cancer activity of histone deacetylase (HDAC)-inhibiting CKD-581 in multiple myeloma (MM) and its pharmacological mechanisms. CKD-581 potently inhibited a broad spectrum of HDAC isozymes. It concentration-dependently inhibited proliferation of hematologic cancer cells including MM (MM.1S and RPMI8226) and T cell lymphoma (HH and MJ). It increased the expression of the dishevelled binding antagonist of β-catenin 3 (DACT3) in T cell lymphoma and MM cells, and decreased the expression of c-Myc and β-catenin in MM cells. Additionally, it enhanced phosphorylated p53, p21, cleaved caspase-3 and the subG1 population, and reversely, downregulated cyclin D1, CDK4 and the anti-apoptotic BCL-2 family. Finally, administration of CKD-581 exerted a significant anti-cancer activity in MM.1S-implanted xenografts. Overall, CKD-581 shows anticancer activity via inhibition of the Wnt/β-catenin signaling pathway in hematologic malignancies. This finding is evidence of the therapeutic potential and rationale of CKD-581 for treatment of MM.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권5호
• /
• pp.2093-2098
• /
• 2015

In patients with multiple myeloma (MM), once-weekly intravenous injection or twice-weekly subcutaneous injection (SC) of bortezomib has been proven to offer non-inferior efficacy to standard twice-weekly intravenous administration, with an improved safety profile. However, whether once-weekly SC bortezomib can further reduce the incidence rate of peripheral neuropathy (PN) and not compromise the efficacy remains to be investigated. 25 patients of MM treated with once-weekly SC bortezomib were reviewed in this study. The median treatment cycles were 4 (range, 2-9 cycles). Complete response (CR) rate was 52%, ${\geq}$very good partial response (VGPR) rate was 72%, and ${\geq}$partial response (PR) rate was 84%. 1-year and 2-year PFS rate was 63.0% and 34.3%, respectively, and 2-year OS rate was 100%. Any grade of PN was reported in 9 patients (36.0%), with 7 patients (28.0%) had grade 1 PN, and 2 patients (8.0%) had grade 2 PN. No patients reported grade 3/4 PN in this cohort. In conclusion, once-weekly subcutaneous administration of bortezomib offers excellent efficacy with a further improved safety profile, especially with regard to PN. It needs to be validated in future prospective randomized trials.

• 임상간호연구
• /
• 제22권1호
• /
• pp.1-9
• /
• 2016

Purpose: This study was done to identify effects of oral care protocol on oral mucositis and oral care performance in hematologic malignancy patients receiving chemotherapy. Methods: The design of this study was a nonequivalent control group pretest-posttest design. Both groups were patients diagnosed with hematologic malignancies who were receiving chemotherapy-each group had 20 patients. In the experimental group, patients were given intensive education on oral care based on the oral care protocol, whereas in the controlled group, each patient was given an educational brochure. Before chemotherapy, and 3 days, 7 days, and 14 days after chemotherapy, oral mucositis status of two groups were assessed using the guide to physical assessment of the oral cavity. Oral care performance was examined before chemotherapy and 14 days later. Results: The experimental group with the oral care protocol showed a significant difference (F=18.15, p<.001) in the oral mucositis status, and also in oral care performance (t=-10.33, p<.001). Conclusion: Findings indicate that the application of the oral care protocol is an effective tool for lowering the occurrence of oral mucositis and enhancing oral care performance in hematologic malignancy patients receiving chemotherapy.

• 한국임상수의학회지
• /
• 제11권2호
• /
• pp.517-524
• /
• 1994

The hematologic values were measured from 64 healthy goats imported from Australia to obtain data about the hematologic values of Australian wild goat. In paper 32 goats imported in March called group 1, 32 goats imported in April called group 2. The result obtained are summarized as follows;, 1 Mean$\pm$SD values and ranges of red blood cell(RBC) were $17.8$\pm$3.0{\times}10^6/${mu}ell$ and 9.9-24.3{\times}10^6/${mu}ell$,$ of hemoglobin(Hb) content 13.8$\pm$1.3 g/㎗ and 10.0-16.1 g/㎗, of packed cell volume(PCV) 37.0$\pm$4.1% and 28.0-47.0%, of mean corpuscular volume(MCV) 21.3$\pm$3.3 fl and 16.4-37.2 fl, of mean corpuscular hemoglobin(MCH) 7.9$\pm$1.1 pg and 6.0-13.3 pg, of mean corpuscular hemoglobin concentration(MCHC) 37. Of 1.9% and 34.0-41.9%, of white blood cell(WBC) $28.6$\pm$9.4{times}10^3/${mu}ell$ and 11.6-49.8{times}10^3/${mu}ell$,$ of neutrophil 38.0$\pm$8.2% and 23.0-61.0%, of lymphocyte 54.0$\pm$8.4% and 32.0-73.0%, monocyte 3.1$\pm$1.3% and 1.0-7.0%, of eosinophil 4.0$\pm$1.9% and 1.0-10.0%, of basophil 0.1$\pm$0.2% and 0-1.0% respectively. 2. There was no significant differences between Group l and Group 2, respectively. 3. There was no significant differences between sexes. 4. Comparing with the values of Korean domestic goat, e values of Australian wild goat were disserent from the values of Korean domestic goat. 5. These hematologic values might be accepted as the hematologic values of Australian wild goat.

• Journal of Oral Medicine and Pain
• /
• 제43권2호
• /
• pp.41-51
• /
• 2018

Purpose: The aim of this study was to evaluate the possibility of utilizing blood tests for the diagnosis of temporomandibular disorders (TMDs) by investigating the hematologic characteristics of TMD patients according to the main source and level of TMD pain and analyzing their interrelationship. Methods: Clinical examination following the research diagnostic criteria for TMD and hematological and psychological evaluations were conducted in 357 TMD patients. Patients were divided into groups according to the main source of pain (myogenous, arthrogenous, and combined pain) and the degree of pain according to the graded chronic pain scale (GCPS). Hematological differences among the groups were statistically analyzed. Results: The C-reactive protein (CRP) level was significantly higher in the arthrogenous pain group compared to the combined pain group (p=0.032). There was no significant difference according to the GCPS classification. There were significant correlations between some of the TMD pain indices and the hematologic indices, and also between the psychological indices and the hematologic indices. Conclusions: This study suggests the possibility of applying blood tests to the diagnosis, treatment and prevention of TMD. Further research should be conducted focusing on the role of CRP in TMD pain with more refined methodology and a longitudinal study design.

• Journal of Hospice and Palliative Care
• /
• 제26권2호
• /
• pp.69-79
• /
• 2023

Purpose: This study aimed to investigate the involvement of patients who died from hematologic neoplasms in the decision-making process surrounding the withdrawal of life-sustaining treatment (LST). Methods: A total of 255 patients diagnosed with hematologic neoplasms who ultimately died following decisions related to LST during their end-of-life period at a university hospital were included in the study. Data were retrospectively obtained from electronic medical records and analyzed utilizing the chi-square test, independent t-test, and logistic regression. Results: In total, 42.0% of patients participated in the decision-making process regarding LST for their hematologic neoplasms, while 58.0% of decisions were made with family involvement. Among these patients, 65.1% died in general wards and 34.9% in intensive care units (ICUs) as a result of decisions such as the suspension of LST. The period from the LST decision to death was longer when the decision was made by the patient (average, 27.15 days) than when it was made by the family (average, 7.48 days). Most decisions were made by doctors and family members in the ICU, where only 20.6% of patients exercised their right to make decisions regarding LST, a rate considerably lower than 79.4% observed in general wards. Decisions to withhold or withdraw LST were more commonly made by patients themselves than by their families. Conclusion: The key to discussing the decision to suspend hospice care and LST is respecting the patient's self-determination. If a patient is lucid prior to admission to the ICU, considerations about suspending LST should involve the patient input.

• 대한수의학회지
• /
• 제29권4호
• /
• pp.433-436
• /
• 1989

임상적으로 건강한 진도개 203두의 혈액치(血液値)를 조사(調査)하였다. 203두에는 암수가 다 포함되어 있었으며 개의 연령은 3개월에서 10세까지 이었다. 적혈구수(赤血球數), 혈색소량(血色素量), 적혈구용적(赤血球容積) 그리고 호산구수(好酸球數) 등은 개의 연령과 함께 증가하였다. 진도개에서 나타난 높은 호산구수(好酸球數)는 심장사상충증(心臟絲狀蟲症)과 벼룩의 감염에 의한 피부염(皮膚炎)때문인 것으로 생각된다.

• 대한한의학회지
• /
• 제37권4호
• /
• pp.30-35
• /
• 2016

Objectives: The patients who had arteriosclerotic occlusive disease were treated by reperforating procedures or vessel replacing operations. We divided them by two groups. one(control group) is treated by Pletaal(cilostazole), the other(CP group) is by Pletaal with cardiotonic pills(CP). Methods : Control group was treated by Pletaal, CP group was treated by Pretaal with CP for 8 weeks. We primarily evaluated the outcomes by visual analogue scale(VAS) of pain, coldness, numbness, and edema, secondarily hematologic tests. Results : Coldness, numbness and edema were reduced at both groups. In CP group, the VAS dropped more sharply than control group, but not significant. Otherwise, there was significant reduction of VAS on pain. In hematologic tests, there were no abnormal results of all items. Conclusion : The therapy of Pletaal with CP is effective to relieve PRS specially in pain and safety on hematologic tests.

• Biomolecules & Therapeutics
• /
• 제8권3호
• /
• pp.213-216
• /
• 2000

In vivo administration of Leucostim, a human recombinant granulocyte colony-stimulating factor (G-CSF), was evaluated for the effects on survival, hematologic recovery, and colony forming unit- spleen (CFU-5) in murine bone marrow transplantation (BMT) model. Sublethally irradiated (9 Gy) mice received bone marrow cells from untreated mice, and then were treated with G-CSF subcutaneously at doses of 2.5,5, or $10\mu\textrm{g}$/kg or vehicle solution (control) for 14 days from one day after BMT. There was no effect of irradiation and BMT on mortality. The repeated subcutaneous injections of Leucostim for 14 days post- BMT significantly facilitated hematologic recovery compared with vehicle control in a dose-dependent manner. Moreover, mice treated with Leucostim had significantly increased numbers of CFU-s colonies on day 10 post-BMT. These results suggest that Leucostim, a new G-CSF, has beneficial effects on hematologic reconstitution after BMT.

• 셀메드
• /
• 제13권5호
• /
• pp.20.1-20.3
• /
• 2023

Objective: A case report on the improvement of patients with hematologic malignancies by Ortho-Cellular Nutrition Therapy (OCNT). Methods: A 69-year-old Korean female diagnosed with Stage 4 ACUTE LYMPHOBLASTIC Leukemia (ALL) had a very low platelet count of 8000/µl. Results: The platelet count improved to its normal level after Ortho-Cellular Nutrition Therapy (OCNT). Conclusion: Ortho-Cellular Nutrition Therapy (OCNT) is effective in relieving the symptoms of acute lymphoblastic leukemia patients with thrombocytopenia.